You searched for "nAMD"
Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
Brolucizumab in age-related macular degeneration, HAWK Study
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Anatomical and functional outcomes following switching from aflibercept to ranibizumab in NARMD
This is a six-month, prospective, single-arm study in the UK and Germany. A total of 100 patients were enrolled (one in the primary failure group, 99 in the suboptimal treatment response group), treated three-monthly intravitreal ranibizumab injections (0.5mg), and then...Advances and developments in medical retina
The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...Considerations in the management of retinal disorders
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
RPE tears after intravitreal Lucentis
The current hypothesis regarding retinal pigment epithelium (RPE) tears is the contraction and fibrosis in choroidal neovascularisation (CNV) tissue after anti-VEGF therapy can induce rips in the overlying RPE. This South Korean study aimed to identify the association between RPE...
Aflibercept (AF) for age-related macular degeneration (ARMD): four-year outcomes of a ‘’treat-and-extend’ (T&E) regimen with exit-strategy
This is a retrospective observational study of 82 patients, between 2014 to 2016 from Switzerland of treatment-naive patients with nARMD, treated with AF, with specific T&E protocol without a loading phase and predefined exit criteria and patients were observed three...Biomarkers reveal how patients with glaucoma may respond to treatment
Markers in the blood that predict whether glaucoma patients are at higher risk of continued loss of vision following conventional treatment have been identified by researchers at UCL and Moorfields Eye Hospital.
